Oropouche in pregnancy: fetal loss and brain abnormalities, now with a comparison group

The edition in brief

A prospective cohort of 544 pregnant women in Rio de Janeiro state found confirmed Oropouche virus infection associated with roughly three times the risk of adverse maternal outcomes (18% vs 7%; aRR 2.90), including fetal loss and haemorrhage, and with adverse infant outcomes (aRR 9.18, wide interval); 8% of infants of infected mothers had central nervous system abnormalities, against none of the uninfected. Symptoms did not predict outcome. In a phase 3 trial reported in July, switching 607 virologically suppressed adults from daily bictegravir–emtricitabine–tenofovir alafenamide to once-weekly oral islatravir–lenacapavir was non-inferior at 48 weeks, with no participant above 50 copies/mL on the weekly regimen. The FDA recorded a supplement to Pfizer's linezolid application on 23 October; the record does not specify its content. A meta-analysis of 14 studies (9,802 spinal surgery patients) linked intra-wound vancomycin powder to lower surgical site infection (OR 0.55), but in the four randomised trials alone the effect was not significant (OR 0.73, 0.45–1.18).